Allan Reine, M.D., is a distinguished medical professional currently serving as the Chief Medical Officer at PRIME Medicine Inc., a biotechnology company focused on developing innovative gene editing therapies. Dr. Reine brings a wealth of experience to his role, having spent over two decades in the medical and pharmaceutical industries. He earned his medical degree from Harvard Medical School and completed his residency in internal medicine at Massachusetts General Hospital. His career has been marked by a dedication to advancing medical treatments and improving patient outcomes. Prior to joining PRIME Medicine Inc., Dr. Reine held several key positions that have shaped his expertise in clinical development and medical affairs. He served as the Vice President of Clinical Development at Genzyme, where he was instrumental in the successful development and launch of several groundbreaking therapies for rare diseases. His leadership and strategic vision were pivotal in navigating complex clinical trials and securing regulatory approvals. Dr. Reine's work has been recognized with numerous awards, including the prestigious Innovator in Medicine Award from the American Medical Association. In his current role at PRIME Medicine Inc., Dr. Reine is responsible for overseeing the clinical development of the company's gene editing platform. His strategic oversight ensures that the company's therapeutic candidates progress efficiently through clinical trials, with a focus on safety and efficacy. Dr. Reine's commitment to scientific excellence and patient-centric care continues to drive PRIME Medicine Inc.'s mission to revolutionize the treatment of genetic disorders. His leadership is a cornerstone of the company's efforts to bring life-changing therapies to patients around the world.